杨士伟,张薇,周玉杰

• 1:首都医科大学附属北京安贞医院心内科北京市心肺血管疾病研究所

摘要(Abstract)：

心力衰竭是各种心脏疾病的严重表现或晚期阶段，死亡率与住院率居高不下，解决上述问题成为迫切的临床需求。近年来，在探索置入式血流动力学监测设备指导心力衰竭治疗的研究中发现，尽管发病诱因不同，各种心力衰竭患者中均可观察到显著的左心房压力升高。房间隔分流装置可以降低心力衰竭患者左心房高负荷，从而改善患者临床症状、运动耐量及预后。目前已有数项小规模临床研究探索通过置入心房分流装置治疗射血分数降低或保留的心力衰竭，结果显示通过心房分流可改善血流动力学参数与症状，提高运动耐量与生活质量，甚至可能降低死亡率，但依然存在争议，还有待大样本、前瞻、随机对照试验进一步评价。目前建议对患者的适应证进行严格把控。

关键词(KeyWords)： 心力衰竭;介入治疗;房间隔分流装置

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 杨士伟,张薇,周玉杰

参考文献(References)：

• [1] McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). With the special contribution of the Heart Failure Association(HFA)of the ESC[J]. Eur J Heart Fail,2022,24(1):4-131.
• [2] Mosterd A,Hoes AW. Clinical epidemiology of heart failure[J].Heart,2007,93(9):1137-1146.
• [3]马丽媛，王增武，樊静，等.《中国心血管健康与疾病报告2021》概要[J].中国介入心脏病学杂志，2022,30(7):481-496.
• [4] Metra M,Teerlink JR. Heart failure[J]. Lancet,2017,390(10106):1981-1995.
• [5] Maggioni AP,Dahlstr?m U,Filippatos G,et al. EURObservational research programme:regional differences and 1-year follow-up results of the heart failure pilot survey(ESC-HF Pilot)[J]. Eur J Heart Fail,2013,15(7):808-817.
• [6] Butler J,Djatche LM,Lautsch D,et al. Representativeness of the VICTORIA trial population in clinical practice:analysis of the PINNACLE registry[J]. J Card Fail,2021,27(12):1374-1381.
• [7] Griffin JM,Borlaug BA,Komtebedde J,et al. Impact o f interatrial shunts on invasive hemodynamics and exercise tolerance in patients with heart failure[J]. J Am Heart Assoc,2020,9(17):e016760.
• [8] Gerber Y,Weston SA,Redfi eld MM,et al. A contemporary appraisal of the heart failure epidemic in Olmsted County,Minnesota,2000 to 2010[J]. JAMA Intern Med,2015,175(6):996-1004.
• [9] Pocock SJ,Ariti CA,McMurray JJV,et al. Predicting survival in heart failure:a risk score based on 39 372 patients from 30studies[J]. Eur Heart J,2013,34(19):1404-1413.
• [10] Ritzema J,Troughton R,Melton I,et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure[J]. Circulation,2010,121(9):1086-1095.
• [11] Abraham WT,Adamson PB,Bourge RC,et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure:a randomised controlled trial[J]. Lancet,2011,377(9766):658-666.
• [12] Ewert P,Berger F,Nagdyman N,et al. Masked left ventricular restriction in elderly patients with atrial septal defects:a contraindication for closure[J]? Catheter Cardiovasc Interv,2001,52(2):177-180.
• [13] Bashi VV,Ravikumar E,Jairaj PS,et al. Coexistent mitral valve disease with left-to-right shunt at the atrial level:clinical profi le,hemodynamics,and surgical considerations in 67 consecutive patients[J]. Am Heart J,1987,114(6):1406-1414.
• [14] Aiyagari RM,Rocchini AP,Remenapp RT,et al. Decompression of the left atrium during extracorporeal membrane oxygenation using a transseptal cannula incorporated into the circuit[J]. Crit Care Med,2006,34(10):2603-2606.
• [15] Seib PM,Faulkner SC,Erickson CC,et al. Blade and balloon atrial septostomy for left heart decompression in patients with severe ventricular dysfunction on extracorporeal membrane oxygenation[J]. Catheter Cardiovasc Interv,1999,46(2):179-186.
• [16] Kaye DM,Petrie MC,McKenzie S,et al. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction[J]. ESC Heart Fail,2019,6(1):62-69.
• [17] Shah SJ,Feldman T,Ricciardi MJ,et al. One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure(REDUCE LAP-HFⅠ)trial:a randomized clinical trial[J]. JAMA Cardiol,2018,3(10):968-977.
• [18] Wessler J,Kaye D,Gustafsson F,et al. Impact of baseline hemodynamics on the effects of a transcatheter interatrial shunt device in heart failure with preserved ejection fraction[J]. Circ Heart Fail,2018,11(8):e004540.
• [19] S?ndergaard L,Reddy V,Kaye D,et al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure[J].Eur J Heart Fail,2014,16(7):796-801.
• [20] Guimaraes L,Lindenfeld J,Sandoval J,et al. Interatrial shunting for heart failure:current evidence and future perspectives[J]. EuroIntervention,2019,15(2):164-171.
• [21] Shah SJ,Borlaug BA,Chung ES,et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction(REDUCE LAP-HFⅡ)：a randomised,multicentre,blinded,sham-controlled trial[J]. Lancet,2022,399(10330):1130-1140.
• [22] Shang X,Liu M,Zhong Y,et al. Clinical study on the treatment of chronic heart failure with a novel D-shant atrium shunt device[J]. ESC Heart Fail,2022,9(3):1713-1720.
• [23]中国医师协会心血管内科医师分会结构性心脏病专业委员会，中国医师协会心血管内科医师分会心力衰竭专业委员会，中国医师协会心血管外科医师分会结构性心脏病专业委员会，等.房间隔分流器治疗射血分数保留心力衰竭：中国专家认识和建议[J].中国介入心脏病学杂志，2020,28(12):661-666.